Series BHealthUnited States · CambridgeJun 09, 2026

City Therapeutics raises $99.5M Series B (United States, Jun 2026)

$99.5M
$99.5M Series B
Browse investors in United States →
Generated social card
City Therapeutics social card
Headline

City Therapeutics Secures $99.5M Series B for RNAi - Ventureburn

About

City Therapeutics is a biotechnology company focused on developing RNA interference (RNAi) therapies. Their innovative platform utilizes engineered RNAi trigger molecules to deliver treatments beyond the liver, targeting diseases such as thromboembolic disorders and Stargardt disease. The recent $99.5 million funding will support the advancement of their clinical pipeline.

Article summary

City Therapeutics Secures $99.5M Series B for RNAi  Ventureburn

Founder
John Maraganore
John Maraganore
CEO & Co-founder
Investors · 8
6 hidden
Viking Global InvestorsLead
FUND
Sofinnova Investments
FUND
Sign up free · see all 8 investors
Related rounds
Jun 28, 2026Delphi Digital$40.0MSeries BUnited States
Jun 27, 2026Hera$27.0MSeries AUnited States
Jun 27, 2026Securitize$400.0M—United States
Jun 27, 2026Generate Biomedicines$700.0MSeries CUnited States
City Therapeutics raises $99.5M Series B (United States, June 2026) | Datapile